ReviewCancer treatment reviews2007
Use of comparative proteomics to identify potential resistance mechanisms in cancer treatment.
Review in Cancer treatment reviews, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Lung cancer organoids: models for preclinical research and precision medicine.Frontiers in oncology · 2023Review
- Investigation of brain damage mechanism in middle cerebral artery occlusion/reperfusion rats based on i-TRAQ quantitative proteomics.Experimental brain research · 2021Article
- 14-3-3σ and Its Modulators in Cancer.Pharmaceuticals (Basel, Switzerland) · 2020Review
- Proteomics analysis indicated the protein expression pattern related to the development of fetal conotruncal defects.Journal of cellular physiology · 2019Article
- Proteomic approach toward determining the molecular background of pazopanib resistance in synovial sarcoma.Oncotarget · 2017Article
- Suppression of ERK1/2 and hypoxia pathways by four Phyllanthus species inhibits metastasis of human breast cancer cells.Journal of food and drug analysis · 2016Article
- Nucleophosmin1 associated with drug resistance and recurrence of bladder cancer.Clinical and experimental medicine · 2015Article
- Prediction of individual response to anticancer therapy: historical and future perspectives.Cellular and molecular life sciences : CMLS · 2015Review
- Proteomics of cancer cell lines resistant to microtubule-stabilizing agents.Molecular cancer therapeutics · 2014Article
- Determinants of 14-3-3σ protein dimerization and function in drug and radiation resistance.The Journal of biological chemistry · 2013Article
- Targeting the MHC Class II antigen presentation pathway in cancer immunotherapy.Oncoimmunology · 2012Article
- Comparative proteomic analysis of paclitaxel sensitive A549 lung adenocarcinoma cell line and its resistant counterpart A549-Taxol.Journal of cancer research and clinical oncology · 2011Article
- Quantitative proteomic and interaction network analysis of cisplatin resistance in HeLa cells.PloS one · 2011Article
- Identification of a new peptide for fibrosarcoma tumor targeting and imaging in vivo.Journal of biomedicine & biotechnology · 2010Article
- Bisphenol, npcRNAs and Utero-Ovarian Feed-Back Control of Breast Cancer Chemosensitivity.Environmental health perspectives · 2009Article
- Genomic and oncoproteomic advances in detection and treatment of colorectal cancer.World journal of surgical oncology · 2009Review
- Innovations, challenges and future prospects of oncoproteomics.Molecular oncology · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Drug resistance is a major problem in successful cancer chemotherapy. Many molecular mechanisms that are responsible for drug resistance are known whereas others have yet to be discovered. Determining the exact mechanism activated in a particular case (clinical or laboratory) is a difficult task. Recently, proteomics has been applied to investigate drug resistance mechanisms in model cancer cell lines. As a result, novel mechanisms of resistance have been discovered and known mechanisms of resistance confirmed. In this paper, we wish to review recent developments and progresses in the application of proteomic tools to identify known and novel drug resistance mechanisms in drug-selected model cancer cell lines. Our combined analyses of multiple proteomic studies of various drug resistant cancer cell lines revealed that many mechanisms of resistance likely exist in any given drug-selected cancer cell line and that common mechanisms of resistance may be selected in a spectrum of cancer cell lines. These observations suggest that combination therapies targeting multiple mechanisms to sensitize drug resistant cancers may be necessary to eradicate cancers in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.